• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Quipt Home Medical Corp.

    12/11/24 4:06:09 PM ET
    $QIPT
    Misc Health and Biotechnology Services
    Health Care
    Get the next $QIPT alert in real time by email
    SC 13G 1 quipt_sc13g.htm SC 13G quipt_sc13g.htm

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

    (Amendment No. __)*

     

    Quipt Home Medical Corp.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    74880P104

    (CUSIP Number)

     

    June 6, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐

    Rule 13d-1(b)

     

     

     

     

    ☒

    Rule 13d-1(c)

     

     

     

     

    ☐

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 74880P104

    Page 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    Forager Fund, L.P.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    2,129,970

    6

     

    SHARED VOTING POWER

     

    0 

    7

     

    SOLE DISPOSITIVE POWER

     

    2,129,970 

    8

     

    SHARED DISPOSITIVE POWER

     

    0 

     

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,129,970 

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ☐

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.0%(1)

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    PN

     

    (1)

    Calculated based on 42,571,000 shares of common stock of the Issuer as of March 31, 2024, as reported on the Issuer’s Report of Foreign Private Issuer on Form 6-K for the period ended March 31, 2024, filed on May 15, 2024.

     

     

     

     

    CUSIP No. 74880P104

    Page 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSONS

     

    Forager Capital Management, LLC 

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ☐ (b) ☐ 

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH REPORTING

    PERSON

    WITH

    5

     

    SOLE VOTING POWER

     

    2,129,970(1) 

    6

     

    SHARED VOTING POWER

     

    0 

    7

     

    SOLE DISPOSITIVE POWER

     

    2,129,970(1)

    8

     

    SHARED DISPOSITIVE POWER

     

    0 

     

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,129,970(1) 

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ☐

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.0%(2)

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    IA

     

    (1)

    Shares reported in this table are held by Forager Fund, L.P., of which the Reporting Person is the general partner.

    (2)

    Calculated based on 42,571,000 shares of common stock of the Issuer as of March 31, 2024, as reported on the Issuer’s Report of Foreign Private Issuer on Form 6-K for the period ended March 31, 2024, filed on May 15, 2024.

     

     

     

     

    CUSIP No. 74880P104

    Page 4 of 7 Pages

     

    1

     

    NAME OF REPORTING PERSONS

     

    Edward Kissel

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ☐ (b) ☐

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH REPORTING

    PERSON

    WITH

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    2,129,970(1)

    7

     

    SOLE DISPOSITIVE POWER

     

    0 

    8

     

    SHARED DISPOSITIVE POWER

     

    2,129,970(1)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,129,970(1) 

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ☐

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.0%(2)

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    HC; IN 

     

    (1)

    These shares are held by Forager Fund, L.P., of which Forager Capital Management, LLC is the general partner. The Reporting Person is a managing partner of Forager Capital Management, LLC.

    (2)

    Calculated based on 42,571,000 shares of common stock of the Issuer as of March 31, 2024, as reported on the Issuer’s Report of Foreign Private Issuer on Form 6-K for the period ended March 31, 2024, filed on May 15, 2024.

     

     

     

     

    CUSIP No. 74880P104

    Page 5 of 7 Pages

     

    1

     

    NAME OF REPORTING PERSONS

     

    Robert MacArthur

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ☐ (b)☐ 

    3

     

    SEC USE ONLY

     

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH REPORTING

    PERSON

    WITH

    5

     

    SOLE VOTING POWER

     

    0

    6

     

    SHARED VOTING POWER

     

    2,129,970(1)

    7

     

    SOLE DISPOSITIVE POWER

     

    0

    8

     

    SHARED DISPOSITIVE POWER

     

    2,129,970(1)

     

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,129,970(1) 

    10

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ☐

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.0%(2)

    12

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    HC; IN

     

    (1)

    These shares are held by Forager Fund, L.P., of which Forager Capital Management, LLC is the general partner. The Reporting Person is a managing partner of Forager Capital Management, LLC.

    (2)

    Calculated based on 42,571,000 shares of common stock of the Issuer as of March 31, 2024, as reported on the Issuer’s Report of Foreign Private Issuer on Form 6-K for the period ended March 31, 2024, filed on May 15, 2024.

     

     

     

     

    CUSIP No. 74880P104

    Page 6 of 7 Pages

     

    ITEM 1(a).

    NAME OF ISSUER

     

     

     

    Quipt Home Medical Corp. (the “Issuer”)

     

     

    ITEM 1(b).

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

     

     

     

    1019 Town Drive

    Wilder, Kentucky 41076

     

     

    ITEM 2(a).

    NAME OF PERSONS FILING

     

     

     

    This joint statement on Schedule 13G is being filed by Forager Fund, L.P., a Delaware limited partnership (the “Fund”), Forager Capital Management, LLC, a Delaware limited liability company and the general partner of the Fund (the “General Partner”), Edward Kissel and Robert MacArthur (collectively, the “Reporting Persons”).

     

     

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to this Schedule 13G, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

     

    ITEM 2(b).

    ADDRESS OF PRINCIPAL BUSINESS OFFICE

     

     

     

    The business address of each of the Reporting Persons is 2025 3rd Ave. N, Suite 350, Birmingham, AL 35203.

     

     

    ITEM 2(c).

    CITIZENSHIP

     

     

     

    The Fund is a Delaware limited partnership. The General Partner is a Delaware limited liability company. Each of Messrs. Kissel and MacArthur is a citizen of the United States.

     

     

    ITEM 2(d).

    TITLE OF CLASS OF SECURITIES

     

     

     

    Common stock (the “Common Stock”).

     

     

    ITEM 2(e).

    CUSIP NUMBER

     

     

     

    74880P104

     

     

    ITEM 3.

    Not applicable.

     

     

    ITEM 4.

    OWNERSHIP

     

     

     

    The Reporting Persons, in the aggregate, beneficially own 2,129,970 shares of Common Stock of the Issuer, representing approximately 5.0% of such class of securities. The beneficial ownership of each Reporting Person is as follows: each of the Fund, the General Partner and Messrs. Kissel and MacArthur beneficially owns 2,129,970 shares of Common Stock representing approximately 5.0% of the class. The percentages of beneficial ownership reported herein, and on each Reporting Person’s cover page to this Schedule 13G, are based on a total of 42,571,000 shares of Common Stock as of March 31, 2024, as reported on the Issuer’s Report of Foreign Private Issuer on Form 6-K for the period ended March 31, 2024, filed on May 15, 2024.

     

     

     

      

    CUSIP No. 74880P104

    Page 7 of 7 Pages

     

     

    Each of the Fund and the General Partner has the sole power to vote and dispose of 2,129,970 shares of Common Stock. Each of Messrs. Kissel and MacArthur has the shared power to vote and dispose of 2,129,970 shares of Common Stock. The amounts and percentages of beneficial ownership reported herein are as of June 6, 2024.

     

     

    ITEM 5.

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

     

     

    Not applicable.

     

     

    ITEM 6.

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

     

     

    Not applicable.

     

     

    ITEM 7.

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

     

     

     

    Not applicable.

     

     

    ITEM 8.

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     

     

     

    Not applicable.

     

     

    ITEM 9.

    NOTICE OF DISSOLUTION OF GROUP

     

     

     

    Not applicable.

     

     

    ITEM 10.

    CERTIFICATION

     

     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

       

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    DATE:

    December 11, 2024

     

     

     

     

     

     

    FORAGER FUND, L.P.

     

     

     

     

     

     

    By:

    Forager Capital Management, LLC,

     

     

     

    its General Partner

     

     

     

     

     

     

    By:

    /s/ Robert MacArthur

     

     

     

    Robert MacArthur

     

     

     

    Managing Partner

     

     

     

     

     

     

    FORAGER CAPITAL MANAGEMENT, LLC 

     

     

     

     

     

     

    By:

    /s/ Robert MacArthur

     

     

     

    Robert MacArthur

     

     

     

    Managing Partner

     

     

     

     

     

     

    EDWARD KISSEL

     

     

     

     

     

     

    /s/ Edward Kissel

     

     

    Edward Kissel

     

     

     

     

     

     

    ROBERT MACARTHUR 

     

     

     

     

     

     

    /s/ Robert MacArthur

     

     

    Robert MacArthur

     

     

     

     

     

    Exhibit 1

     

    JOINT FILING AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree, as of December 11, 2024, that only one statement containing the information required by Schedule 13G, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of common stock of Quipt Home Medical Corp., a British Columbia, Canada corporation, and such statement to which this Joint Filing Agreement is attached as Exhibit 1 is filed on behalf of each of the undersigned.

     

     

    FORAGER FUND, L.P.

     

     

     

     

     

     

    By:

    Forager Capital Management, LLC,

     

     

     

    its General Partner

     

     

     

     

     

     

    By:

    /s/ Robert MacArthur

     

     

     

    Robert MacArthur

     

     

     

    Managing Partner

     

     

     

     

     

     

    FORAGER CAPITAL MANAGEMENT, LLC 

     

     

     

     

     

     

    By:

    /s/ Robert MacArthur

     

     

     

    Robert MacArthur

     

     

     

    Managing Partner

     

     

     

     

     

     

    EDWARD KISSEL

     

     

     

     

     

     

    /s/ Edward Kissel

     

     

    Edward Kissel

     

     

     

     

     

     

    ROBERT MACARTHUR 

     

     

     

     

     

     

    /s/ Robert MacArthur

     

     

    Robert MacArthur

     

     

     

     

     

    Exhibit 2

     

    CONFIRMING STATEMENT

     

    This Statement confirms that the undersigned has authorized and designated Robert MacArthur to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 and Schedules 13D and 13G (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned’s ownership of or transactions in securities of Quipt Home Medical Corp., a British Columbia, Canada corporation.  The authority of Robert MacArthur under this Statement shall continue until the undersigned is no longer required to file any of Forms 3, 4 and 5 and Schedules 13D and 13G with regard to the undersigned’s ownership of or transactions in securities of Regional Management Corp., unless earlier revoked in writing.  The undersigned acknowledges that Robert MacArthur is not assuming any of the undersigned’s responsibilities to comply with Section 16 or Section 13 of the Securities Exchange Act of 1934, as amended.

     

    Dated: December 11, 2024 /s/ Edward Kissel

     

     

    Edward Kissel  

     

     

     

     

    Exhibit 3

     

    CONFIRMING STATEMENT

     

    This Statement confirms that the undersigned has authorized and designated Edward Kissel to execute and file on the undersigned’s behalf all Forms 3, 4 and 5 and Schedules 13D and 13G (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned’s ownership of or transactions in securities of Quipt Home Medical Corp., a British Columbia, Canada corporation.  The authority of Edward Kissel under this Statement shall continue until the undersigned is no longer required to file any of Forms 3, 4 and 5 and Schedules 13D and 13G with regard to the undersigned’s ownership of or transactions in securities of Regional Management Corp., unless earlier revoked in writing.  The undersigned acknowledges that Edward Kissel is not assuming any of the undersigned’s responsibilities to comply with Section 16 or Section 13 of the Securities Exchange Act of 1934, as amended.

     

    Dated: December 11, 2024 

     

    /s/ Robert MacArthur

     

     

     

    Robert MacArthur

     

     

     

     

    Get the next $QIPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QIPT

    DatePrice TargetRatingAnalyst
    5/17/2024Mkt Perform → Underperform
    Raymond James
    2/16/2024Outperform → Mkt Perform
    Raymond James
    6/14/2023$11.00Buy
    Canaccord Genuity
    10/20/2021$7.50Buy
    The Benchmark Company
    10/20/2021$7.50Buy
    Benchmark
    More analyst ratings

    $QIPT
    Financials

    Live finance-specific insights

    See more
    • Quipt Home Medical Reports Fiscal Second Quarter 2025 Results

      CINCINNATI, May 12, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fiscal second quarter 2025 financial results and operational highlights. These results pertain to the three and six months ended March 31, 2025, and are reported in United States dollars. Conference Call Quipt will host its Earnings Conference Call on Tuesday, May 13, 2025 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing 1 (833) 752-3722 or 1 (647) 846-8549. A live webcast of the call will be accessible via the investor section of the

      5/12/25 5:00:00 PM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Quipt Home Medical Corp. to Announce Fiscal Second Quarter 2025 Financial Results on May 12, 2025

      CINCINNATI, April 30, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the "Company") (NASDAQ:QIPT) (TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal Second quarter 2025 financial results on Monday, May 12, 2025, after market close. Gregory Crawford, Chief Executive Officer, and Hardik Mehta, Chief Financial Officer, will host a conference call for the investment community on Tuesday, May 13, 2025, at 10:00 a.m. (ET). The call-in numbers for participants are: Canada/US Toll Free:1 (833) 752 3722International:1 (647) 846 8549   A live webcast of the call will be accessible via the investor section of the Company's w

      4/30/25 7:30:00 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Quipt Home Medical Reports First Quarter Fiscal Year 2025 Financial Results

      CINCINNATI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its first quarter fiscal year 2025 financial results and operational highlights. These results pertain to the three months ended December 31, 2024 and are reported in U.S. Dollars. Conference Call Quipt will host its Earnings Conference Call on Tuesday, February 11, 2025 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing 1 (844) 763-8274 or 1 (647) 484-8814. A live webcast of the call will be accessible via the Company's website at https:/

      2/10/25 5:00:00 PM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care

    $QIPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quipt Home Medical Reports Fiscal Second Quarter 2025 Results

      CINCINNATI, May 12, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fiscal second quarter 2025 financial results and operational highlights. These results pertain to the three and six months ended March 31, 2025, and are reported in United States dollars. Conference Call Quipt will host its Earnings Conference Call on Tuesday, May 13, 2025 at 10:00 a.m. (ET). Interested parties may participate in the call by dialing 1 (833) 752-3722 or 1 (647) 846-8549. A live webcast of the call will be accessible via the investor section of the

      5/12/25 5:00:00 PM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Quipt Home Medical Corp. to Announce Fiscal Second Quarter 2025 Financial Results on May 12, 2025

      CINCINNATI, April 30, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the "Company") (NASDAQ:QIPT) (TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal Second quarter 2025 financial results on Monday, May 12, 2025, after market close. Gregory Crawford, Chief Executive Officer, and Hardik Mehta, Chief Financial Officer, will host a conference call for the investment community on Tuesday, May 13, 2025, at 10:00 a.m. (ET). The call-in numbers for participants are: Canada/US Toll Free:1 (833) 752 3722International:1 (647) 846 8549   A live webcast of the call will be accessible via the investor section of the Company's w

      4/30/25 7:30:00 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Quipt Home Medical Unveils Strategic Priorities for 2025 to Enhance Shareholder Value and Announces Voting Results from its Annual General Meeting

      CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is pleased to announce its strategic priorities for calendar 2025 and the voting results from its annual general meeting of shareholders held on March 17, 2025 (the "Meeting") in Sarasota, Florida. The total number of shares represented in person or by proxy at the Meeting was 31,400,043, representing 72.87% of the total issued and outstanding shares in the capital of the Company. As it relates to its strategic priorities for 2025, the Company remains committed to returning to hist

      3/24/25 7:30:00 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care

    $QIPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wessel Brian Joseph was granted 183,135 shares, increasing direct ownership by 1,297% to 197,260 units (SEC Form 4)

      4 - Quipt Home Medical Corp. (0001540013) (Issuer)

      3/25/25 7:37:03 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Chief Accounting Officer Roehrig Thomas was granted 110,000 shares, increasing direct ownership by 175% to 173,000 units (SEC Form 4)

      4 - Quipt Home Medical Corp. (0001540013) (Issuer)

      3/25/25 7:36:22 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Chief Compliance Officer Miles Mark Alan was granted 110,000 shares (SEC Form 4)

      4 - Quipt Home Medical Corp. (0001540013) (Issuer)

      3/25/25 7:35:41 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care

    $QIPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Exec VP Operations Gamble Patrick Dennis bought $41,634 worth of shares (17,000 units at $2.45), increasing direct ownership by 74% to 40,057 units (SEC Form 4)

      4 - Quipt Home Medical Corp. (0001540013) (Issuer)

      12/30/24 4:05:11 PM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care

    $QIPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Quipt Home Medical Corp.

      SC 13D - Quipt Home Medical Corp. (0001540013) (Subject)

      12/11/24 4:07:36 PM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Quipt Home Medical Corp.

      SC 13G/A - Quipt Home Medical Corp. (0001540013) (Subject)

      12/11/24 4:06:42 PM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G filed by Quipt Home Medical Corp.

      SC 13G - Quipt Home Medical Corp. (0001540013) (Subject)

      12/11/24 4:06:09 PM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care

    $QIPT
    SEC Filings

    See more
    • Quipt Home Medical Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Quipt Home Medical Corp. (0001540013) (Filer)

      5/12/25 5:08:56 PM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Quipt Home Medical Corp.

      10-Q - Quipt Home Medical Corp. (0001540013) (Filer)

      5/12/25 5:04:41 PM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Quipt Home Medical Corp.

      SCHEDULE 13D/A - Quipt Home Medical Corp. (0001540013) (Subject)

      4/2/25 8:16:50 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care

    $QIPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Quipt Home Medical downgraded by Raymond James

      Raymond James downgraded Quipt Home Medical from Mkt Perform to Underperform

      5/17/24 7:45:25 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Quipt Home Medical downgraded by Raymond James

      Raymond James downgraded Quipt Home Medical from Outperform to Mkt Perform

      2/16/24 8:29:00 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Canaccord Genuity resumed coverage on Quipt Home Medical with a new price target

      Canaccord Genuity resumed coverage of Quipt Home Medical with a rating of Buy and set a new price target of $11.00

      6/14/23 8:58:25 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care

    $QIPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Quipt Home Medical Unveils Strategic Priorities for 2025 to Enhance Shareholder Value and Announces Voting Results from its Annual General Meeting

      CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is pleased to announce its strategic priorities for calendar 2025 and the voting results from its annual general meeting of shareholders held on March 17, 2025 (the "Meeting") in Sarasota, Florida. The total number of shares represented in person or by proxy at the Meeting was 31,400,043, representing 72.87% of the total issued and outstanding shares in the capital of the Company. As it relates to its strategic priorities for 2025, the Company remains committed to returning to hist

      3/24/25 7:30:00 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Quipt Home Medical Announces Voting Results from Its Annual General and Special Meeting of Shareholders

      CINCINNATI, March 28, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the "Company") (NASDAQ:QIPT) (TSX:QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its annual general and special meeting of shareholders held on March 27, 2024 (the "Meeting") in Wilder, Kentucky. The total number of shares represented in person or by proxy at the Meeting was 25,432,699, representing 60.4% of the total issued and outstanding shares in the capital of the Company. Election of Directors The four candidates nominated for election to the Company's Board of Directors (the "Board") and listed in the Company's manageme

      3/28/24 7:30:00 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care
    • Quipt Home Medical Announces New Independent Board Member

      CINCINNATI, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSXV:QIPT), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, announced today that Mr. Brian J. Wessel has joined the Board of Directors of the Company as an Independent Director and Chair of the Audit Committee. Mr. Wessel is a senior business executive with over 34 years of global client service, operational and financial expertise. As a former senior partner at Ernst & Young ("EY"), Mr. Wessel provided audit and advisory services to public, private, and private-equity-owned companies across multiple industry sectors. Additio

      2/3/22 7:30:00 AM ET
      $QIPT
      Misc Health and Biotechnology Services
      Health Care